Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid generic competition, wrote Connor Hart for the Wall Street Journal earlier…Newer drugs, one for a “rare heart disease,” Acoramidis, and a non-hormonal treatment for menopause, elinzanetant, are seen making up for Xarelto’s expected decline, noted the WSJ. BridgeBio Pharma (BBIO), the Palo Alto, Calif., biotechnology company has acoramidis’ U.S. rights, added the story…
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer: Gadoquatrane met primary, secondary endpoints in Phase III QUANTI studies
- BridgeBio receives positive CHMP opinion for acoramidis for ATTR-CM treatment
- OneMedNet announces collaboration with Bayer’s AI Innovation Platform
- Bayer announces FDA acceptance of Nubeqa sNDA
- Bayer price target lowered to EUR 22 from EUR 28 at Berenberg